Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD, discusses what factors go into his decision to use polatuzumab plus bendamustine and rituximab in certain patients with relapsed/refractory diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses his experience using the combination of polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the study design and results of the phase 2 trial of the antibody-drug conjugate polatuzumab vedotin-piiq plus bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the Bruton’s kinase inhibitors available for patients with B-cell malignancies and how they compare.

Ian W. Flinn, MD, PhD, director, Blood Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase I story which examined cerdulatinib in patients with relapsed/refractory B-cell malignancies.

Ian W. Flinn, MD, PhD, discusses the mechanism of action and toxicity profile of duvelisib (IPI-145). Duvelisib is being studied for the treatment of hematologic malignancies.

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, gives an overview of two ongoing clinical trials looking at IPI-145 for the treatment of hematologic malignancies.